The Patent Finder

Suven Life Sciences Limited

31 patents currently held · Updated Nov 15, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

2
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Muscarinic M1 Receptor Positive Allosteric Modulators (US 10,308,620) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 2 fees due Jan 14, 2027
  • 1 fee due Sep 30, 2027
    The maintenance fee for Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors (US 10,603,323) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
  • 1 fee due Nov 3, 2027
    The maintenance fee for Acrylamide compounds as histamine H3 receptor ligands (US 9,328,092) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,875,605N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,735,423Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,079,888Compounds as histamine H3 receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,079,894Heteroaryl compounds as 5-HT4 receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,636,335Heteroaryl compounds as 5-HT4 receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,328,092Acrylamide compounds as histamine H3 receptor ligands
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,540,321Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,951,045Indazole compounds as 5-HT4 receptor agonists
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,802,896Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,010,527Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 31 patents shown.
Pro members see all 31.
Pro members: see all 31 patents
Also on record, not counted in the 31: 3 patents in force now held by others · 21 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 1 abandoned · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited